GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vera Therapeutics Inc (NAS:VERA) » Definitions » PB Ratio

Vera Therapeutics (Vera Therapeutics) PB Ratio : 19.91 (As of May. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Vera Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-07), Vera Therapeutics's share price is $45.545. Vera Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $2.29. Hence, Vera Therapeutics's PB Ratio of today is 19.91.

The historical rank and industry rank for Vera Therapeutics's PB Ratio or its related term are showing as below:

VERA' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 21.97
Current: 19.89

During the past 5 years, Vera Therapeutics's highest PB Ratio was 21.97. The lowest was 0.00. And the median was 0.00.

VERA's PB Ratio is ranked worse than
95.58% of 1312 companies
in the Biotechnology industry
Industry Median: 2.47 vs VERA: 19.89

During the past 12 months, Vera Therapeutics's average Book Value Per Share Growth Rate was -17.30% per year.

Back to Basics: PB Ratio


Vera Therapeutics PB Ratio Historical Data

The historical data trend for Vera Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vera Therapeutics PB Ratio Chart

Vera Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
- - 8.17 7.00 6.72

Vera Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 2.18 5.06 4.92 6.72

Competitive Comparison of Vera Therapeutics's PB Ratio

For the Biotechnology subindustry, Vera Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vera Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vera Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Vera Therapeutics's PB Ratio falls into.



Vera Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Vera Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=45.545/2.288
=19.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Vera Therapeutics  (NAS:VERA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Vera Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Vera Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vera Therapeutics (Vera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8000 Marina Boulevard, Suite 120, Brisbane, CA, USA, 94005
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Executives
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Marshall Fordyce director, officer: President and CEO C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Celia Lin officer: Chief Medical Officer C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Joanne Curley officer: Chief Development Officer C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Sean Grant officer: Chief Financial Officer C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Beth C Seidenberg director
Sofinnova Management X-a, L.l.c. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Longitude Capital Partners Iv, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Fund, L.p. 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Patrick G Enright director, 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Abingworth Bioventures 8 Lp 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004

Vera Therapeutics (Vera Therapeutics) Headlines

From GuruFocus

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

By Stock market mentor Stock market mentor 02-02-2023

FMR LLC Adjusts Stake in Vera Therapeutics Inc

By GuruFocus Research 11-14-2023